Dicks Sporting Goods Inc vs Illumina, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $206.29 (market cap $19.16B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.34% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DKS | ILMN | |
|---|---|---|
Market Cap | $19.16B | $28.96B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $205.10 |
52-Week Low | $187.78 | $91.00 |
Enterprise Value | $25.95B | $30.32B |
Dividend Yield | 2.34% | — |
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $208.84, up 5.15% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals with support at $201 and resistance at $213. Fundamentally, the company maintains solid profitability with 20.9% ROE and 4.71% net margin, though cash flow trends show modest net outflows. Recent news highlights analyst upgrades and the upcoming Q2 earnings call on August 25th.
The investment outlook remains positive with 59% analyst buy ratings and a $263.22 consensus target representing 26% upside. Key risks include potential fiduciary duty investigations and competitive pressures in sporting goods retail. The company's consistent earnings beats and expanding women's sports investments provide catalysts, though investors should monitor cash flow sustainability and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →